US Archives - Page 68 of 184 - European Medical Journal

IDSA Guideline Update on Infliximab for Severe COVID-19

The latest clinical practice guideline update provides new recommendations on the use of infliximab for hospitalized adults with severe or critical COVID-19.

Hospitalizations Fall in Chronic Lymphocytic Leukemia Thanks to Continuity of Care

Patients with chronic lymphocytic leukemia (CLL) who consistently saw the same oncologist or hematologist experienced significantly fewer emergency room visits and hospitalizations, according to a large real-world study of nearly 6,000 individuals treated with covalent Bruton tyrosine kinase inhibitor (cBTKi) therapy.

Alzheimer’s Studies Evolve with Bigger, Slower Trials

Randomized clinical trials in Alzheimer’s disease have grown substantially in scale and complexity over the past three decades, with modern studies increasingly designed to capture slower and more subtle therapeutic effects.

Interferon Nasal Spray Shows Protective Effect Against COVID-19

Daily prophylaxis with interferon-alpha (IFN-α) nasal spray significantly reduced the risk of COVID-19 infection in adult patients with cancer, according to findings from a randomized, double-blinded, placebo-controlled trial.

Remote Care Halves COPD Burden and Sharpens Inhaler Technique

Telemedicine follow-up significantly improved quality of life and inhaler use techniques among patients with advanced chronic obstructive pulmonary disease (COPD), according to a randomized controlled trial.

ChatGPT Outperforms Google in SLE Biologic Therapy Guidance

ChatGPT demonstrates higher accuracy and completeness than Google Web Search when providing information about biologic therapy for systemic lupus erythematosus (SLE), according to a new comparative study.

Chronic Bronchitis Significantly Associated With Psoriasis

Adults with psoriasis may be more likely to also have chronic bronchitis, according to new U.S. population-based findings.

Closing COVID-19 Protection Gaps

This infographic reviews the persistent burden of COVID-19 in vulnerable populations and the clinical rationale for early post-exposure…

Obesity-Restricted Benefits of GLP-1 Therapy in Lung Cancer

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), widely used for diabetes and weight reduction, may offer significant benefits in improving outcomes for patients with non-small cell lung cancer (NSCLC), according to new clinical and preclinical evidence.

GLP-1 Agonists Show Motor Benefits in Parkinson’s

Emerging evidence suggests that GLP-1 receptor agonists, widely used for type 2 diabetes mellitus (T2DM), may offer therapeutic benefits in Parkinson’s disease (PD).